MTX clearance is more important for intermediate-risk ALL.
Evans
W E
WE
Schell
M J
MJ
Pui
C H
CH
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D006801:Humans; D008727:Methotrexate / Q000493:pharmacokinetics*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000378:metabolism*; D012307:Risk Factors
D008727:Methotrexate